Literature DB >> 10871827

New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis.

L J Balcer1, M L Baier, V S Pelak, R J Fox, S Shuwairi, S L Galetta, G R Cutter, M G Maguire.   

Abstract

The quantitative assessment of visual function in multiple sclerosis (MS) clinical trials has been limited to Snellen visual acuity. The purpose of this study was to examine the inter-rater reliability and test characteristics of a new visual outcome measure, the Low-Contrast Sloan Letter Charts, in patients with MS and visually-asymptomatic volunteers. Contrast letter acuity scores (letter scores) were measured at each of four contrast levels (100, 5, 1.25 and 0.6%) by two independent raters. Inter-rater agreement was described with the intraclass correlation coefficient (ICC) and comparison of mean scores. Excellent inter-rater agreement (ICC=0.86 - 0.95) was demonstrated at each contrast level among MS patients (n=100) and visually-asymptomatic volunteers (n=33). Average letter scores at the lowest contrast level (0.6%) were highly variable in the MS group, even among patients with visual acuities of 20/20 or better, and among those who required no assistance for ambulation. Low-Contrast Sloan Letter Chart testing is a highly reliable method of visual assessment, and provides information on an aspect of neurologic impairment in MS which is not captured by Snellen visual acuity or ambulation status. This new method demonstrates excellent potential as a visual function outcome measure for future MS clinical trials.

Entities:  

Mesh:

Year:  2000        PMID: 10871827     DOI: 10.1177/135245850000600305

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  51 in total

1.  Monocular and binocular low-contrast visual acuity and optical coherence tomography in pediatric multiple sclerosis.

Authors:  Amy T Waldman; Girish Hiremath; Robert A Avery; Amy Conger; Stacy L Pineles; Michael J Loguidice; Lauren S Talman; Kristin M Galetta; Michael J Shumski; James Wilson; E'tona Ford; Amy M Lavery; Darrel Conger; Benjamin M Greenberg; Jonas H Ellenberg; Elliot M Frohman; Laura J Balcer; Peter A Calabresi
Journal:  Mult Scler Relat Disord       Date:  2013-05-01       Impact factor: 4.339

2.  Diffusion tensor imaging of the optic tracts in multiple sclerosis: association with retinal thinning and visual disability.

Authors:  Hormuzdiyar H Dasenbrock; Seth A Smith; Arzu Ozturk; Sheena K Farrell; Peter A Calabresi; Daniel S Reich
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

Review 3.  Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis.

Authors:  Madhan Kolappan; Andrew P D Henderson; Thomas M Jenkins; Claudia A M Wheeler-Kingshott; Gordon T Plant; Alan J Thompson; David H Miller
Journal:  J Neurol       Date:  2009-03-18       Impact factor: 4.849

4.  Evaluation of optic neuropathy in multiple sclerosis using low-contrast visual evoked potentials.

Authors:  M J Thurtell; E Bala; S S Yaniglos; J C Rucker; N S Peachey; R J Leigh
Journal:  Neurology       Date:  2009-12-01       Impact factor: 9.910

5.  TuebingenCSTest - a useful method to assess the contrast sensitivity function.

Authors:  Tim Schilling; Arne Ohlendorf; Alexander Leube; Siegfried Wahl
Journal:  Biomed Opt Express       Date:  2017-02-10       Impact factor: 3.732

6.  Ganglion cell loss in relation to visual disability in multiple sclerosis.

Authors:  Scott D Walter; Hiroshi Ishikawa; Kristin M Galetta; Reiko E Sakai; Daniel J Feller; Sam B Henderson; James A Wilson; Maureen G Maguire; Steven L Galetta; Elliot Frohman; Peter A Calabresi; Joel S Schuman; Laura J Balcer
Journal:  Ophthalmology       Date:  2012-02-23       Impact factor: 12.079

7.  Retinal architecture and mfERG: Optic nerve head component response characteristics in MS.

Authors:  Zane S Schnurman; Teresa C Frohman; Shin C Beh; Darrel Conger; Amy Conger; Shiv Saidha; Steven Galetta; Peter A Calabresi; Ari J Green; Laura J Balcer; Elliot M Frohman
Journal:  Neurology       Date:  2014-04-30       Impact factor: 9.910

8.  Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.

Authors:  Magí Andorrà; Salut Alba-Arbalat; Anna Camos-Carreras; Iñigo Gabilondo; Elena Fraga-Pumar; Ruben Torres-Torres; Irene Pulido-Valdeolivas; Ana I Tercero-Uribe; Ana M Guerrero-Zamora; Santiago Ortiz-Perez; Irati Zubizarreta; Nuria Sola-Valls; Sara Llufriu; Maria Sepulveda; Eugenia Martinez-Hernandez; Thais Armangue; Yolanda Blanco; Pablo Villoslada; Bernardo Sanchez-Dalmau; Albert Saiz; Elena H Martinez-Lapiscina
Journal:  JAMA Neurol       Date:  2020-02-01       Impact factor: 18.302

Review 9.  Evolution of Visual Outcomes in Clinical Trials for Multiple Sclerosis Disease-Modifying Therapies.

Authors:  Rachel C Nolan; Omar Akhand; John-Ross Rizzo; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2018-06       Impact factor: 3.042

10.  Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.

Authors:  Lindsay Horton; Amy Conger; Darrel Conger; Gina Remington; Teresa Frohman; Elliot Frohman; Benjamin Greenberg
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.